Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies
Abstract
:1. Introduction
2. CPPs as Molecular Carriers in Cancer
2.1. CPP-Cargo Complexes Internalization
2.2. Delivery of Chemotherapeutic Agents
2.3. Delivery of Nucleic Acids
2.4. Delivery of Proteins
3. CPP-Based Anti-Cancer Therapy Optimization
3.1. Chemical Modifications to Enhance Therapeutic Delivery and Stability
3.2. Tumor-Homing CPPs
3.3. CPP-Antibody Conjugates
3.4. Activatable CPPs
3.5. Passive Targeting with Intracellular Specificity
4. Summary and Concluding Remarks
Author Contributions
Funding
Conflicts of Interest
References
- Schaffhausen, J. Remaining hurdles to effective cancer therapy. Trends Pharmacol. Sci. 2015, 36, v. [Google Scholar] [CrossRef] [PubMed]
- Groves, J.T. Membrane Mechanics in Living Cells. Dev. Cell 2019, 48, 15–16. [Google Scholar] [CrossRef] [PubMed]
- Swain, S.; Sahu, P.K.; Beg, S.; Babu, S.M. Nanoparticles for Cancer Targeting: Current and Future Directions. Curr. Drug Deliv. 2016, 13, 1290–1302. [Google Scholar] [CrossRef] [PubMed]
- Deshpande, P.P.; Biswas, S.; Torchilin, V.P. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond.) 2013, 8, 1509–1528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, J.; Liu, E.; Yu, Z.; Pei, X.; Chen, S.; Zhang, P.; Shin, M.-C.; Gong, J.; He, H.; Yang, V.C. CPP-Assisted Intracellular Drug Delivery, What Is Next? Int. J. Mol. Sci. 2016, 17, 1892. [Google Scholar] [CrossRef] [PubMed]
- Joliot, A.; Pernelle, C.; Deagostini-Bazin, H.; Prochiantz, A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. USA 1991, 88, 1864–1868. [Google Scholar] [CrossRef] [PubMed]
- Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269, 10444–10450. [Google Scholar] [PubMed]
- CPPsite 2.0: A Repository of Experimentally Validated Cell-Penetrating Peptides. Available online: https://www.ncbi.nlm.nih.gov/pubmed/26586798 (accessed on 20 January 2019).
- Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55, 1179–1188. [Google Scholar] [CrossRef]
- Frankel, A.D.; Bredt, D.S.; Pabo, C.O. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 1988, 240, 70–73. [Google Scholar] [CrossRef] [PubMed]
- Elmquist, A.; Lindgren, M.; Bartfai, T.; Langel, U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. 2001, 269, 237–244. [Google Scholar] [CrossRef] [PubMed]
- Pooga, M.; Hällbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J. 1998, 12, 67–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Langel, U.; Pooga, M.; Kairane, C.; Zilmer, M.; Bartfai, T. A galanin-mastoparan chimeric peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain. Regul. Pept. 1996, 62, 47–52. [Google Scholar] [CrossRef]
- Morris, M.C.; Vidal, P.; Chaloin, L.; Heitz, F.; Divita, G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 1997, 25, 2730–2736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morris, M.C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 2001, 19, 1173–1176. [Google Scholar] [CrossRef] [PubMed]
- Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 2000, 97, 13003–13008. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oehlke, J.; Scheller, A.; Wiesner, B.; Krause, E.; Beyermann, M.; Klauschenz, E.; Melzig, M.; Bienert, M. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1998, 1414, 127–139. [Google Scholar] [CrossRef]
- Delaroche, D.; Aussedat, B.; Aubry, S.; Chassaing, G.; Burlina, F.; Clodic, G.; Bolbach, G.; Lavielle, S.; Sagan, S. Tracking a new cell-penetrating (W/R) nonapeptide, through an enzyme-stable mass spectrometry reporter tag. Anal. Chem. 2007, 79, 1932–1938. [Google Scholar] [CrossRef] [PubMed]
- Ragin, A.D.; Morgan, R.A.; Chmielewski, J. Cellular import mediated by nuclear localization signal Peptide sequences. Chem. Biol. 2002, 9, 943–948. [Google Scholar] [CrossRef]
- Mai, J.C.; Shen, H.; Watkins, S.C.; Cheng, T.; Robbins, P.D. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 2002, 277, 30208–30218. [Google Scholar] [CrossRef] [PubMed]
- Johansson, H.J.; El-Andaloussi, S.; Holm, T.; Mäe, M.; Jänes, J.; Maimets, T.; Langel, Ü. Characterization of a Novel Cytotoxic Cell-penetrating Peptide Derived From p14ARF Protein. Mol. Ther. 2008, 16, 115–123. [Google Scholar] [CrossRef] [PubMed]
- Taylor, B.N.; Mehta, R.R.; Yamada, T.; Lekmine, F.; Christov, K.; Chakrabarty, A.M.; Green, A.; Bratescu, L.; Shilkaitis, A.; Beattie, C.W.; et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 2009, 69, 537–546. [Google Scholar] [CrossRef] [PubMed]
- Bechara, C.; Sagan, S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013, 587, 1693–1702. [Google Scholar] [CrossRef] [PubMed]
- Copolovici, D.M.; Langel, K.; Eriste, E.; Langel, Ü. Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano 2014, 8, 1972–1994. [Google Scholar] [CrossRef] [PubMed]
- Guo, Z.; Peng, H.; Kang, J.; Sun, D. Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed. Rep. 2016, 4, 528–534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jafari, S.; Maleki Dizaj, S.; Adibkia, K. Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. Bioimpacts 2015, 5, 103–111. [Google Scholar] [CrossRef] [PubMed]
- Madani, F.; Lindberg, S.; Langel, Ü.; Futaki, S.; Gräslund, A. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. J. Biophys. 2011, 2011, 414729. [Google Scholar] [CrossRef] [PubMed]
- Guidotti, G.; Brambilla, L.; Rossi, D. Cell-Penetrating Peptides: From Basic Research to Clinics. Trends Pharmacol. Sci. 2017, 38, 406–424. [Google Scholar] [CrossRef] [PubMed]
- Ramsey, J.D.; Flynn, N.H. Cell-penetrating peptides transport therapeutics into cells. Pharmacol. Ther. 2015, 154, 78–86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feni, L.; Neundorf, I. The Current Role of Cell-Penetrating Peptides in Cancer Therapy. Adv. Exp. Med. Biol. 2017, 1030, 279–295. [Google Scholar] [PubMed]
- Bolhassani, A.; Jafarzade, B.S.; Mardani, G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides 2017, 87, 50–63. [Google Scholar] [CrossRef] [PubMed]
- Trabulo, S.; Cardoso, A.L.; Mano, M.; de Lima, M.C.P. Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and Generation of Delivery Systems. Pharmaceuticals 2010, 3, 961–993. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zahid, M.; Robbins, P. Cell-Type Specific Penetrating Peptides: Therapeutic Promises and Challenges. Molecules 2015, 20, 13055–13070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skotland, T.; Iversen, T.G.; Torgersen, M.L.; Sandvig, K. Cell-penetrating peptides: Possibilities and challenges for drug delivery in vitro and in vivo. Molecules 2015, 20, 13313–13323. [Google Scholar] [CrossRef] [PubMed]
- Derivery, E.; Bartolami, E.; Matile, S.; Gonzalez-Gaitan, M. Efficient Delivery of Quantum Dots into the Cytosol of Cells Using Cell-Penetrating Poly(disulfide)s. J. Am. Chem. Soc. 2017, 139, 10172–10175. [Google Scholar] [CrossRef] [PubMed]
- Cosgrave, L.; Devocelle, M.; Forster, R.J.; Keyes, T.E. Multimodal cell imaging by ruthenium polypyridyl labelled cell penetrating peptides. Chem. Commun. (Camb.) 2010, 46, 103–105. [Google Scholar] [CrossRef] [PubMed]
- Fu, L.-S.; Wu, Y.-R.; Fang, S.-L.; Tsai, J.-J.; Lin, H.-K.; Chen, Y.-J.; Chen, T.-Y.; Chang, M.D.-T. Cell Penetrating Peptide Derived from Human Eosinophil Cationic Protein Decreases Airway Allergic Inflammation. Sci. Rep. 2017, 7, 12352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gurney, L.R.I.; Taggart, J.; Tong, W.-C.; Jones, A.T.; Robson, S.C.; Taggart, M.J. Inhibition of Inflammatory Changes in Human Myometrial Cells by Cell Penetrating Peptide and Small Molecule Inhibitors of NFκB. Front. Immunol. 2018, 9, 2966. [Google Scholar] [CrossRef] [PubMed]
- Peng, J.; Rao, Y.; Yang, X.; Jia, J.; Wu, Y.; Lu, J.; Tao, Y.; Tu, W. Targeting neuronal nitric oxide synthase by a cell penetrating peptide Tat-LK15/siRNA bioconjugate. Neurosci. Lett. 2017, 650, 153–160. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Caballero, A.; Gadotti, V.M.; Chen, L.; Zamponi, G.W. A cell-permeant peptide corresponding to the cUBP domain of USP5 reverses inflammatory and neuropathic pain. Mol. Pain 2016, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, W.-Y.; Murata, E.; Ueda, K.; Kuroda, Y.; Cao, M.-H.; Abe, M.; Shigemi, K.; Hirose, M. A synthetic cell-penetrating peptide antagonizing TrkA function suppresses neuropathic pain in mice. J. Pharmacol. Sci. 2010, 114, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Jia, L.; Gorman, G.S.; Coward, L.U.; Noker, P.E.; McCormick, D.; Horn, T.L.; Harder, J.B.; Muzzio, M.; Prabhakar, B.; Ganesh, B.; et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 2011, 68, 513–524. [Google Scholar] [CrossRef] [PubMed]
- Betts, C.A.; Wood, M.J.A. Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr. Pharm. Des. 2013, 19, 2948–2962. [Google Scholar] [CrossRef] [PubMed]
- Koutsokeras, A.; Purkayastha, N.; Purkayashta, N.; Rigby, A.; Subang, M.C.; Sclanders, M.; Vessillier, S.; Mullen, L.; Chernajovsky, Y.; Gould, D. Generation of an efficiently secreted, cell penetrating NF-κB inhibitor. FASEB J. 2014, 28, 373–381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gurbel, P.A.; Bliden, K.P.; Turner, S.E.; Tantry, U.S.; Gesheff, M.G.; Barr, T.P.; Covic, L.; Kuliopulos, A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 189–197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nasrollahi, S.A.; Fouladdel, S.; Taghibiglou, C.; Azizi, E.; Farboud, E.S. A peptide carrier for the delivery of elastin into fibroblast cells. Int. J. Dermatol. 2012, 51, 923–929. [Google Scholar] [CrossRef] [PubMed]
- Pujals, S.; Fernández-Carneado, J.; Ludevid, M.D.; Giralt, E. D-SAP: A new, noncytotoxic, and fully protease resistant cell-penetrating peptide. ChemMedChem 2008, 3, 296–301. [Google Scholar] [CrossRef] [PubMed]
- Walrant, A.; Cardon, S.; Burlina, F.; Sagan, S. Membrane Crossing and Membranotropic Activity of Cell-Penetrating Peptides: Dangerous Liaisons? Acc. Chem. Res. 2017, 50, 2968–2975. [Google Scholar] [CrossRef] [PubMed]
- Crombez, L.; Morris, M.C.; Heitz, F.; Divita, G. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. Methods Mol. Biol. 2011, 764, 59–73. [Google Scholar] [PubMed]
- Gros, E.; Deshayes, S.; Morris, M.C.; Aldrian-Herrada, G.; Depollier, J.; Heitz, F.; Divita, G. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim. Biophys. Acta 2006, 1758, 384–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nischan, N.; Herce, H.D.; Natale, F.; Bohlke, N.; Budisa, N.; Cardoso, M.C.; Hackenberger, C.P.R. Covalent attachment of cyclic TAT peptides to GFP results in protein delivery into live cells with immediate bioavailability. Angew. Chem. Int. Ed. Engl. 2015, 54, 1950–1953. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, E.J.B.; Yoshida, S.; Kamei, N.; Iwamae, R.; Khafagy, E.-S.; Olsen, J.; Rahbek, U.L.; Pedersen, B.L.; Takayama, K.; Takeda-Morishita, M. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J. Control. Release 2014, 189, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8, 848–866. [Google Scholar] [CrossRef] [PubMed]
- Kawamoto, S.; Takasu, M.; Miyakawa, T.; Morikawa, R.; Oda, T.; Futaki, S.; Nagao, H. Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: Importance of attractive force between cell-penetrating peptides and lipid head group. J. Chem. Phys. 2011, 134, 095103. [Google Scholar] [CrossRef] [PubMed]
- Allolio, C.; Magarkar, A.; Jurkiewicz, P.; Baxová, K.; Javanainen, M.; Mason, P.E.; Šachl, R.; Cebecauer, M.; Hof, M.; Horinek, D.; et al. Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore. Proc. Natl. Acad. Sci. USA 2018, 115, 11923–11928. [Google Scholar] [CrossRef] [PubMed]
- Matsuzaki, K.; Sugishita, K.; Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of Gram-negative bacteria. FEBS Lett. 1999, 449, 221–224. [Google Scholar] [CrossRef] [Green Version]
- Mayor, S.; Pagano, R.E. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 603–612. [Google Scholar] [CrossRef] [PubMed]
- Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 2005, 280, 15300–15306. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, A.; Pellegrini, V.; Arcangeli, C.; Fittipaldi, A.; Giacca, M.; Beltram, F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 2003, 8, 284–294. [Google Scholar] [CrossRef]
- Nakase, I.; Noguchi, K.; Aoki, A.; Takatani-Nakase, T.; Fujii, I.; Futaki, S. Arginine-rich cell-penetrating peptide-modified extracellular vesicles for active macropinocytosis induction and efficient intracellular delivery. Sci. Rep. 2017, 7, 1991. [Google Scholar] [CrossRef] [PubMed]
- Niu, X.; Gao, Z.; Qi, S.; Su, L.; Yang, N.; Luan, X.; Li, J.; Zhang, Q.; An, Y.; Zhang, S. Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells. Int. J. Nanomed. 2018, 13, 4895–4911. [Google Scholar] [CrossRef] [PubMed]
- Wu, X.; Gehring, W. Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis. Biochem. Biophys. Res. Commun. 2014, 443, 1136–1140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szabó, I.; Orbán, E.; Schlosser, G.; Hudecz, F.; Bánóczi, Z. Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells. Eur. J. Med. Chem. 2016, 115, 361–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Movafegh, B.; Jalal, R.; Mohammadi, Z.; Aldaghi, S.A. Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death. Anticancer Agents Med. Chem. 2018, 18, 1448–1456. [Google Scholar] [CrossRef] [PubMed]
- Zhang, P.; Cheetham, A.G.; Lock, L.L.; Cui, H. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug. Chem. 2013, 24, 604–613. [Google Scholar] [CrossRef] [PubMed]
- Soudy, R.; Chen, C.; Kaur, K. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. J. Med. Chem. 2013, 56, 7564–7573. [Google Scholar] [CrossRef] [PubMed]
- Yu, M.; Li, X.; Huang, X.; Zhang, J.; Zhang, Y.; Wang, H. New Cell Penetrating Peptide (KRP) with Multiple Physicochemical Properties Endows Doxorubicin with Tumor Targeting and Improves Its Therapeutic Index. ACS Appl. Mater. Interfaces 2018, 11, 2448–2458. [Google Scholar] [CrossRef] [PubMed]
- Duan, Z.; Chen, C.; Qin, J.; Liu, Q.; Wang, Q.; Xu, X.; Wang, J. Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer. Drug Deliv. 2017, 24, 752–764. [Google Scholar] [CrossRef] [PubMed]
- Izabela, R.; Jarosław, R.; Magdalena, A.; Piotr, R.; Ivan, K. Transportan 10 improves the anticancer activity of cisplatin. Naunyn Schmiedebergs Arch. Pharmacol. 2016, 389, 485–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, Y.; Zhao, X.; Geng, J.; Guo, X.; Ma, J.; Wang, H.; Liu, C. Intracellular delivery of nucleic acid by cell-permeable hPP10 peptide. J. Cell. Physiol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.W.; Hwang, Y.E.; Lee, J.Y.; Sohn, J.-H.; Sung, B.H.; Kim, S.C. VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide. J. Microbiol. Biotechnol. 2018, 28, 367–374. [Google Scholar] [CrossRef] [PubMed]
- Viallard, C.; Larrivée, B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 2017, 20, 409–426. [Google Scholar] [CrossRef] [PubMed]
- Baoum, A.; Xie, S.-X.; Fakhari, A.; Berkland, C. “Soft” Calcium Crosslinks Enable Highly Efficient Gene Transfection Using TAT Peptide. Pharm. Res. 2009, 26, 2619–2629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fang, W.B.; Yao, M.; Brummer, G.; Acevedo, D.; Alhakamy, N.; Berkland, C.; Cheng, N. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget 2016, 7, 49349–49367. [Google Scholar] [PubMed] [Green Version]
- Mandal, P.K.; Biswas, S.; Mandal, G.; Purohit, S.; Gupta, A.; Majumdar Giri, A.; Roy Chowdhury, S.; Bhattacharyya, A. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression. Immunobiology 2018, 223, 151–161. [Google Scholar] [CrossRef] [PubMed]
- Steel, R.; Cowan, J.; Payerne, E.; O’Connell, M.A.; Searcey, M. Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction. ACS Med. Chem. Lett. 2012, 3, 407–410. [Google Scholar] [CrossRef] [PubMed]
- Menegon, S.; Columbano, A.; Giordano, S. The Dual Roles of NRF2 in Cancer. Trends Mol. Med. 2016, 22, 578–593. [Google Scholar] [CrossRef] [PubMed]
- Yuan, J.; Yan, R.; Krämer, A.; Eckerdt, F.; Roller, M.; Kaufmann, M.; Strebhardt, K. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004, 23, 5843–5852. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morris, M.C.; Gros, E.; Aldrian-Herrada, G.; Choob, M.; Archdeacon, J.; Heitz, F.; Divita, G. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res. 2007, 35, e49. [Google Scholar] [CrossRef] [PubMed]
- Turner, J.J.; Jones, S.; Fabani, M.M.; Ivanova, G.; Arzumanov, A.A.; Gait, M.J. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol. Dis. 2007, 38, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999, 285, 1569–1572. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Li, M.; Zhang, Z.; Gong, T.; Sun, X. Cell-penetrating peptides as delivery enhancers for vaccine. Curr. Pharm. Biotechnol. 2014, 15, 256–266. [Google Scholar] [CrossRef] [PubMed]
- Pouniotis, D.S.; Apostolopoulos, V.; Pietersz, G.A. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology 2006, 117, 329–339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pouniotis, D.; Tang, C.-K.; Apostolopoulos, V.; Pietersz, G. Vaccine delivery by penetratin: Mechanism of antigen presentation by dendritic cells. Immunol. Res. 2016, 64, 887–900. [Google Scholar] [CrossRef] [PubMed]
- Brooks, N.; Hsu, J.; Esparon, S.; Pouniotis, D.; Pietersz, G.A. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope. Molecules 2018, 23, 2233. [Google Scholar] [CrossRef] [PubMed]
- Shahbazi, S.; Bolhassani, A. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. Int. Immunopharmacol. 2018, 62, 170–180. [Google Scholar] [CrossRef] [PubMed]
- Yamada, T.; Christov, K.; Shilkaitis, A.; Bratescu, L.; Green, A.; Santini, S.; Bizzarri, A.R.; Cannistraro, S.; Gupta, T.K.D.; Beattie, C.W. p28, a first in class peptide inhibitor of cop1 binding to p53. Br. J. Cancer 2013, 108, 2495–2504. [Google Scholar] [CrossRef] [PubMed]
- Mehta, R.R.; Yamada, T.; Taylor, B.N.; Christov, K.; King, M.L.; Majumdar, D.; Lekmine, F.; Tiruppathi, C.; Shilkaitis, A.; Bratescu, L.; et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011, 14, 355–369. [Google Scholar] [CrossRef] [PubMed]
- Jagot-Lacoussiere, L.; Kotula, E.; Villoutreix, B.O.; Bruzzoni-Giovanelli, H.; Poyet, J.-L. A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death. Cancer Res. 2016, 76, 5479–5490. [Google Scholar] [CrossRef] [PubMed]
- Bullenkamp, J.; Tavassoli, M. Signalling of Apoptin. Adv. Exp. Med. Biol. 2014, 818, 11–37. [Google Scholar] [PubMed]
- Tian, L.; Zhang, X.; Haesen, D.; Bravo, J.; Fominaya, J.; Choquet, S.; Zini, J.M.; Loisel, S.; Waelkens, E.; Janssens, V.; et al. Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. Int. J. Pept. Res. Ther. 2018, 24, 479–488. [Google Scholar] [CrossRef]
- Hung, M.-H.; Chen, K.-F. Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. Expert Opin. Ther. Targets 2017, 21, 685–694. [Google Scholar] [CrossRef] [PubMed]
- Marin, G.; Bruzzoni-Giovanelli, H.; Schinella, G. T cell leukemia control via Ras-Raf pathway inhibition with peptides. J. Med. Life 2017, 10, 172–175. [Google Scholar] [PubMed]
- Beez, S.; Demmer, P.; Puccetti, E. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides. PLoS ONE 2012, 7, e48636. [Google Scholar] [CrossRef] [PubMed]
- Baar, M.P.; Brandt, R.M.C.; Putavet, D.A.; Klein, J.D.D.; Derks, K.W.J.; Bourgeois, B.R.M.; Stryeck, S.; Rijksen, Y.; van Willigenburg, H.; Feijtel, D.A.; et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 2017, 169, 132–147. [Google Scholar] [CrossRef] [PubMed]
- Maly, D.J.; Allen, J.A.; Shokat, K.M. A mechanism-based cross-linker for the identification of kinase-substrate pairs. J. Am. Chem. Soc. 2004, 126, 9160–9161. [Google Scholar] [CrossRef] [PubMed]
- Krejci, P. Apoptosis inhibitor 5 (API-5; AAC-11; FIF) is upregulated in human carcinomas in vivo. Oncol. Lett. 2012, 3, 913–916. [Google Scholar] [CrossRef] [PubMed]
- Rigou, P.; Piddubnyak, V.; Faye, A.; Rain, J.-C.; Michel, L.; Calvo, F.; Poyet, J.-L. The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation. EMBO J. 2009, 28, 1576–1588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Faye, A.; Poyet, J.-L. Targeting AAC-11 in cancer therapy. Expert Opin. Ther. Targets 2010, 14, 57–65. [Google Scholar] [CrossRef] [PubMed]
- Song, K.-H.; Kim, S.-H.; Noh, K.H.; Bae, H.C.; Kim, J.H.; Lee, H.-J.; Song, J.; Kang, T.H.; Kim, D.-W.; Oh, S.-J.; et al. Apoptosis inhibitor 5 increases metastasis via Erk-mediated MMP expression. BMB Rep. 2015, 48, 330–335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krejci, P.; Pejchalova, K.; Rosenbloom, B.E.; Rosenfelt, F.P.; Tran, E.L.; Laurell, H.; Wilcox, W.R. The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J. Leukoc. Biol. 2007, 82, 1363–1364. [Google Scholar] [CrossRef] [PubMed]
- Pasquereau-Kotula, E.; Habault, J.; Kroemer, G.; Poyet, J.-L. The anticancer peptide RT53 induces immunogenic cell death. PLoS ONE 2018, 13, e0201220. [Google Scholar] [CrossRef] [PubMed]
- Su, Y.; Doherty, T.; Waring, A.J.; Ruchala, P.; Hong, M. Roles of Arginine and Lysine Residues in the Translocation of a Cell-Penetrating Peptide from 13C, 31P and 19F Solid-State NMR. Biochemistry 2009, 48, 4587–4595. [Google Scholar] [CrossRef] [PubMed]
- Peraro, L.; Kritzer, J.A. Emerging Methods and Design Principles for Cell-Penetrant Peptides. Angew. Chem. Int. Ed. Engl. 2018, 57, 11868–11881. [Google Scholar] [CrossRef] [PubMed]
- El-Sayed, N.S.; Miyake, T.; Shirazi, A.N.; Park, S.E.; Clark, J.; Buchholz, S.; Parang, K.; Tiwari, R. Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine as Molecular Transporters. Molecules 2018, 23, 1590. [Google Scholar] [CrossRef] [PubMed]
- Shirazi, A.N.; Mozaffari, S.; Sherpa, R.T.; Tiwari, R.; Parang, K. Efficient Intracellular Delivery of Cell-Impermeable Cargo Molecules by Peptides Containing Tryptophan and Histidine. Molecules 2018, 23, 1536. [Google Scholar] [CrossRef] [PubMed]
- Yamashita, H.; Misawa, T.; Oba, M.; Tanaka, M.; Naito, M.; Kurihara, M.; Demizu, Y. Development of helix-stabilized cell-penetrating peptides containing cationic α,α-disubstituted amino acids as helical promoters. Bioorg. Med. Chem. 2017, 25, 1846–1851. [Google Scholar] [CrossRef] [PubMed]
- Hällbrink, M.; Kilk, K.; Elmquist, A.; Lundberg, P.; Lindgren, M.; Jiang, Y.; Pooga, M.; Soomets, U.; Langel, Ü. Prediction of Cell-Penetrating Peptides. Int. J. Pept. Res. Ther. 2005, 11, 249–259. [Google Scholar] [CrossRef] [Green Version]
- Hansen, M.; Kilk, K.; Langel, Ü. Predicting cell-penetrating peptides. Adv. Drug Deliv. Rev. 2008, 60, 572–579. [Google Scholar] [CrossRef] [PubMed]
- Karelson, M.; Dobchev, D. Using artificial neural networks to predict cell-penetrating compounds. Expert Opin. Drug Discov. 2011, 6, 783–796. [Google Scholar] [CrossRef] [PubMed]
- Zhang, D.; Wang, J.; Xu, D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J. Control. Release 2016, 229, 130–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmidt, N.; Mishra, A.; Lai, G.H.; Wong, G.C.L. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010, 584, 1806–1813. [Google Scholar] [CrossRef] [PubMed]
- Osman, G.; Rodriguez, J.; Chan, S.Y.; Chisholm, J.; Duncan, G.; Kim, N.; Tatler, A.L.; Shakesheff, K.M.; Hanes, J.; Suk, J.S.; et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J. Control. Release 2018, 285, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Panigrahi, B.; Singh, R.K.; Mishra, S.; Mandal, D. Cyclic peptide-based nanostructures as efficient siRNA carriers. Artif. Cells Nanomed. Biotechnol. 2018, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Khalily, M.P.; Gerekçi, S.; Güleç, E.A.; Özen, C.; Özçubukçu, S. Structure-based design, synthesis and anticancer effect of cyclic Smac-polyarginine peptides. Amino Acids 2018, 50, 1607–1616. [Google Scholar] [CrossRef] [PubMed]
- Kozhikhova, K.V.; Andreev, S.M.; Shilovskiy, I.P.; Timofeeva, A.V.; Gaisina, A.R.; Shatilov, A.A.; Turetskiy, E.A.; Andreev, I.M.; Smirnov, V.V.; Dvornikov, A.S.; et al. A novel peptide dendrimer LTP efficiently facilitates transfection of mammalian cells. Org. Biomol. Chem. 2018, 16, 8181–8190. [Google Scholar] [CrossRef] [PubMed]
- Tesei, G.; Vazdar, M.; Jensen, M.R.; Cragnell, C.; Mason, P.E.; Heyda, J.; Skepö, M.; Jungwirth, P.; Lund, M. Self-association of a highly charged arginine-rich cell-penetrating peptide. Proc. Natl. Acad. Sci. USA 2017, 114, 11428–11433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoyer, J.; Schatzschneider, U.; Schulz-Siegmund, M.; Neundorf, I. Dimerization of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. Beilstein J. Org. Chem. 2012, 8, 1788–1797. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Demizu, Y.; Oba, M.; Okitsu, K.; Yamashita, H.; Misawa, T.; Tanaka, M.; Kurihara, M.; Gellman, S.H. A preorganized β-amino acid bearing a guanidinium side chain and its use in cell-penetrating peptides. Org. Biomol. Chem. 2015, 13, 5617–5620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andaloussi, S.E.L.; Lehto, T.; Mäger, I.; Rosenthal-Aizman, K.; Oprea, I.I.; Simonson, O.E.; Sork, H.; Ezzat, K.; Copolovici, D.M.; Kurrikoff, K.; et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011, 39, 3972–3987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J. 2009, 11, 13–22. [Google Scholar] [CrossRef] [PubMed]
- Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 2009, 61, 704–709. [Google Scholar] [CrossRef] [PubMed]
- Oskolkov, N.; Arukuusk, P.; Copolovici, D.-M.; Lindberg, S.; Margus, H.; Padari, K.; Pooga, M.; Langel, Ü. NickFects, Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides. Int. J. Pept. Res. Ther. 2011, 17, 147. [Google Scholar] [CrossRef]
- Tünnemann, G.; Martin, R.M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006, 20, 1775–1784. [Google Scholar] [CrossRef] [PubMed]
- Shukla, G.S.; Krag, D.N. Phage display selection for cell-specific ligands: Development of a screening procedure suitable for small tumor specimens. J. Drug Target 2005, 13, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Kamada, H.; Okamoto, T.; Kawamura, M.; Shibata, H.; Abe, Y.; Ohkawa, A.; Nomura, T.; Sato, M.; Mukai, Y.; Sugita, T.; et al. Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domain. Biol. Pharm. Bull. 2007, 30, 218–223. [Google Scholar] [CrossRef] [PubMed]
- Pasqualini, R.; Koivunen, E.; Ruoslahti, E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 1995, 130, 1189–1196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Y.; Kang, C.; Liu, F.; Zhou, Y.; Luo, L.; Qiao, H. RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine. Drug Dev. Res. 2017, 78, 283–291. [Google Scholar] [CrossRef] [PubMed]
- Zhou, N.; Wu, J.; Qin, Y.-Y.; Zhao, X.-L.; Ding, Y.; Sun, L.-S.; He, T.; Huang, X.-W.; Liu, C.-B.; Wang, H. Novel peptide MT23 for potent penetrating and selective targeting in mouse melanoma cancer cells. Eur. J. Pharm. Biopharm. 2017, 120, 80–88. [Google Scholar] [CrossRef] [PubMed]
- Lim, K.J.; Sung, B.H.; Shin, J.R.; Lee, Y.W.; Kim, D.J.; Yang, K.S.; Kim, S.C. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS ONE 2013, 8, e66084. [Google Scholar] [CrossRef]
- Xiang, Y.; Shan, W.; Huang, Y. Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2. Int. J. Pharm. 2018, 551, 14–22. [Google Scholar] [CrossRef] [PubMed]
- Shin, M.C.; Zhang, J.; Ah Min, K.; Lee, K.; Moon, C.; Balthasar, J.P.; Yang, V.C. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. J. Control. Release 2014, 194, 197–210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, J.; Shin, M.C.; Liang, Q.; He, H.; Yang, V.C. 15 years of ATTEMPTS: A macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting. J. Control. Release 2015, 205, 58–69. [Google Scholar] [CrossRef] [PubMed]
- Olson, E.S.; Aguilera, T.A.; Jiang, T.; Ellies, L.G.; Nguyen, Q.T.; Wong, E.H.; Gross, L.A.; Tsien, R.Y. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb.) 2009, 1, 382–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, H.; Zhu, J.-Y.; Xu, X.-D.; Qiu, W.-X.; Lei, Q.; Han, K.; Cheng, Y.-J.; Zhang, X.-Z. Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery. ACS Appl. Mater. Interfaces 2015, 7, 16061–16069. [Google Scholar] [CrossRef] [PubMed]
- Xiang, B.; Jia, X.-L.; Qi, J.-L.; Yang, L.-P.; Sun, W.-H.; Yan, X.; Yang, S.-K.; Cao, D.-Y.; Du, Q.; Qi, X.-R. Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int. J. Nanomed. 2017, 12, 2385–2405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Minet, E.; Arnould, T.; Michel, G.; Roland, I.; Mottet, D.; Raes, M.; Remacle, J.; Michiels, C. ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett. 2000, 468, 53–58. [Google Scholar] [CrossRef]
- Karagiota, A.; Kourti, M.; Simos, G.; Mylonis, I. HIF-1α-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia. Cell. Mol. Life Sci. 2019, 76, 809–825. [Google Scholar] [CrossRef] [PubMed]
- Darwish, S.; Sadeghiani, N.; Fong, S.; Mozaffari, S.; Hamidi, P.; Withana, T.; Yang, S.; Tiwari, R.K.; Parang, K. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide. Eur. J. Med. Chem. 2019, 161, 594–606. [Google Scholar] [CrossRef] [PubMed]
Peptide | Sequence | Type | Lenght | Origin | References |
---|---|---|---|---|---|
Antennapedia Penetratin (43–58) | RQIKIWFQNRRMKWKK | Cationic and amphipatic | 16 | Protein-derived | Derossi et al., 1996 [7] |
HIV-1 TAT protein (48–60) | GRKKRRQRRRPPQ | Cationic | 13 | Protein-derived | Green and Loewenstein, 1988; Frankel and Pabo, 1988 [8,9] |
pVEC Cadherin (615–632) | LLIILRRRIRKQAHAHSK | Amphipatic | 18 | Protein-derived | Elmquist et al., 2001 [10] |
Transportan Galanine/Mastoparan | GWTLNSAGYLLGKINLKALAALAKKIL | Amphipatic | 27 | Chimeric | Pooga et al., 1998 [11]; Langel et al., 1996 [12] |
MPG HIV-gp41/SV40 T-antigen | GALFLGFLGAAGSTMGAWSQPKKKRKV | Amphipatic | 27 | Chimeric | Morris et al., 1997 [13] |
Pep-1 HIV-reverse transcriptase/SV40 T-antigen | KETWWETWWTEWSQPKKKRKV | Amphipatic | 21 | Chimeric | Morris et al., 2001 [14] |
Polyarginines | R(n); 6 < n < 12 | Cationic | 6–12 | Synthetic | Wender et al., 2000 [15] |
MAP | KLALKLALKALKAALKLA | Amphipatic | 18 | Synthetic | Oehlke et al., 1998 [16] |
R6W3 | RRWWRRWRR | Cationic | 9 | Synthetic | Delaroche et al., 2007 [17] |
NLS | CGYGPKKKRKVGG | Cationic | 13 | Protein-derived | Ragin et al., 2002 [18] |
8-lysines | KKKKKKKK | Cationic | 8 | Synthetic | Mai et al., 2002 [19] |
ARF (1–22) | MVRRFLVTLRIRRACGPPRVRV | Amphipatic | 22 | Protein-derived | Johansson et al., 2008 [20] |
Azurin-p28 | LSTAADMQGVVTDGMASGLDKDYLKPDD | Anionic | 28 | Protein-derived | Taylor BN et al., 2009 [21] |
CPP | Cargo | Application | Status | Compound | Company | ClinicalTrial.gov ID |
---|---|---|---|---|---|---|
R7 | Cyclosporine A | Psoriasis | Phase II terminated 2003 | PsorBan | CellGate. Inc | N/A |
TAT | δPKC inhibitor | Heart attack | Phase II completed 2011 | KAI-9803 | KAI Pharmaceutical | NCT00785954 |
PTD4 | HSP20 phosphopeptide | Wound healing | Phase II completed 2012 | AZX-100 | Capstone Therapeutics | NCT00825916 |
P28 | P28 | Central Nervous System Tumors | Phase I completed 2013 | P28 | Pediatric Brain Tumor Consortium | NCT01975116 |
P28 | P28 | Solid tumors | Phase I completed 2014 | P28 | CDG Therapeutics. Inc | NCT00914914 |
N/A | N/A | Duchenne Muscular Dystrophy (DMD) | Phase II completed 2015 | AVI-4658 | Sarepta Therapeutics | NCT00844597 |
TAT | JNK-1 | Intraocular inflammation and pain | Phase III completed 2016 | XG-102 | Xigen SA | NCT02235272 |
TAT | JNK-1 | Acute inner ear hearing loss | Phase III completed 2017 | AM-111 | Auris Medical | NCT02561091 |
MTS | Botulinum toxin A | Cervical Dystonia | Phase II completed 2018 | R-002 | Revance Therapeutics | NCT02706795 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Habault, J.; Poyet, J.-L. Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies. Molecules 2019, 24, 927. https://doi.org/10.3390/molecules24050927
Habault J, Poyet J-L. Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies. Molecules. 2019; 24(5):927. https://doi.org/10.3390/molecules24050927
Chicago/Turabian StyleHabault, Justine, and Jean-Luc Poyet. 2019. "Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies" Molecules 24, no. 5: 927. https://doi.org/10.3390/molecules24050927